Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
Article CAS PubMed Google Scholar
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.
Article CAS PubMed Google Scholar
CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.
Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology. 2013;120(1):209– 10]. Ophthalmology. 2012;119(12):2537–2548.
Kornhauser T, Schwartz R, Goldstein M, Neudorfer M, Loewenstein A, Barak A. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol. 2016;254(5):835–44.
Article CAS PubMed Google Scholar
Tadayoni R, Waldstein SM, Boscia F, et al. Individualized stabilization criteria-driven ranibizumab versus laser in Branch Retinal vein occlusion: six-Month results of BRIGHTER. Ophthalmology. 2016;123(6):1332–44.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.
Clark WL, Boyer DS, Heier JS, et al. Intravitreal Aflibercept for Macular Edema following branch retinal vein occlusion: 52-Week results of the VIBRANT study. Ophthalmology. 2016;123(2):330–6.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787–94.
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42(6):807–11.
Lemos V, Cabugueira A, Noronha M, et al. Intraocular pressure in eyes receiving Intravitreal Antivascular endothelial growth factor injections. Ophthalmologica. 2015;233(3–4):162–8.
Article CAS PubMed Google Scholar
Lee JW, Park H, Choi JH, et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 2016;16:69. Published 2016 May 31.
Article PubMed PubMed Central Google Scholar
de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):13248. Published 2020 Aug 6.
Article PubMed PubMed Central Google Scholar
Demirel S, Batioğlu F, Özmert E, Erenler F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res. 2015;40(1):87–92.
Article CAS PubMed Google Scholar
Valverde-Megías A, Ruiz-Calvo A, Murciano-Cespedosa A, Hernández-Ruiz S, Martínez-de-la-Casa JM, García-Feijoo J. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1459–66.
Sobacı G, Güngör R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 2013;6(2):211–5. Published 2013 Apr 18.
PubMed PubMed Central Google Scholar
Shin HJ, Shin KC, Chung H, Kim HC. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014;55(4):2403–11. Published 2014 Apr 15.
Ahn J, Jang K, Sohn J, Park JI, Hwang DD. Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness. Sci Rep. 2021;11(1):5010. Published 2021 Mar 3.
Article CAS PubMed PubMed Central Google Scholar
Zivkovic M, Radosavljevic A, Zlatanovic M, et al. Influence of multiple Anti-VEGF injections on retinal nerve Fiber layer and Ganglion Cell-Inner Plexiform Layer Thickness in patients with exudative age-related Macular Degeneration. Med (Kaunas). 2023;59(1):138. Published 2023 Jan 10.
Jun SY, Hwang DD. Short-term effect of intravitreal brolucizumab injections in patients with neovascular age-related macular degeneration on retinal nerve fiber layer thickness. Sci Rep. 2023;13(1):6685. Published 2023 Apr 24. https://doi.org/10.1038/s41598-023-32024-6.
Wichrowska M, Goździewska E, Kocięcki J. The safety of Anti-VEGF treatment, in the context of the retinal nerve Fibre Layer, in patients with wet age-related Macular Degeneration: a review. Front Biosci (Landmark Ed). 2023;28(9):222.
Article CAS PubMed Google Scholar
Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol. 2015;35(4):473–80.
Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012;53(10):6214–8. Published 2012 Sep 14.
Article CAS PubMed Google Scholar
Yau GL, Campbell RJ, Li C, Sharma S. Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. Can J Ophthalmol. 2015;50(5):345–9.
Wang L, Swaminathan SS, Yang J, et al. Dose-response relationship between Intravitreal injections and retinal nerve Fiber layer thinning in Age-Related Macular Degeneration. Ophthalmol Retina. 2021;5(7):648–54.
Gómez-Mariscal M, Puerto B, Muñoz-Negrete FJ, de Juan V, Rebolleda G. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2221–31.
Cho HK, Kee C. Rate of change in Bruch’s membrane opening-minimum Rim Width and Peripapillary RNFL in early normal tension Glaucoma. J Clin Med. 2020;9(8):2321.
Article CAS PubMed PubMed Central Google Scholar
Choi HS, Joo CW, Park SP, Na KI. A decrease in Bruch’s membrane opening-minimum Rim Area precedes decreased retinal nerve Fiber layer thickness and visual field loss in Glaucoma. J Glaucoma. 2021;30(12):1033–8.
Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359–93.
Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3):H1054–8.
Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53–67.
Article CAS PubMed PubMed Central Google Scholar
Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals. 2005;14(5):207–21.
留言 (0)